Contrasting Immunocore (NASDAQ:IMCR) and Xenetic Biosciences (NASDAQ:XBIO)

Xenetic Biosciences (NASDAQ:XBIO) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Profitability

This table compares Xenetic Biosciences and Immunocore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Immunocore	-4.20%	-4.54%	-1.66%

Institutional & Insider Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Xenetic Biosciences has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Xenetic Biosciences and Immunocore, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
Immunocore	1	5	6	1	2.54

Immunocore has a consensus target price of $56.38, indicating a potential upside of 63.55%. Given Immunocore’s stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than Xenetic Biosciences.

Valuation and Earnings

This table compares Xenetic Biosciences and Immunocore”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98 million	3.24	-$2.68 million	($1.16)	-3.64
Immunocore	$400.02 million	4.44	-$35.51 million	($0.37)	-93.16

Xenetic Biosciences has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Immunocore beats Xenetic Biosciences on 12 of the 15 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.